The identification of amplified ERBB2 as a major driver in approximately 20% of breast cancers and the subsequent development of anti-ERBB2-targeted therapies, such as trastuzumab, turned out to be a major success13. This evidence concerns the gene ERBB2 and breast carcinoma.